The Influence of Opioids on Urokinase Plasminogen Activator on Protein and mRNA Level in MCF-7 Breast Cancer Cell Line

被引：35

作者：

Gach, Katarzyna ^{[1
]}

Szemraj, Janusz ^{[2
]}

Fichna, Jakub ^{[1
]}

Piestrzeniewicz, Mariola ^{[1
]}

Delbro, Dick S. ^{[3
,4
]}

Janecka, Anna ^{[1
]}

机构：

[1] Med Univ Lodz, Dept Biomol Chem, Lodz, Poland

[2] Med Univ Lodz, Dept Biochem, Lodz, Poland

[3] Sahlgrens Univ Hosp, Dept Surg, Gothenburg, Sweden

[4] Univ Karlstad, Dept Chem & Biomed Sci, Karlstad, Sweden

来源：

CHEMICAL BIOLOGY & DRUG DESIGN | 2009年 / 74卷 / 04期

关键词：

gene expression; opioid agonists and antagonists; proliferation; tumor markers; NUCLEUS-TRACTUS-SOLITARII; TUMOR-GROWTH; IN-VITRO; GENE-EXPRESSION; METASTASIS; MORPHINE; INVASION; RECEPTOR; SURVIVAL; SYSTEM;

D O I：

10.1111/j.1747-0285.2009.00875.x

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Urokinase plasminogen activator plays a key role in tumor-associated processes, increasing cancer cell invasion and metastasis, and is therefore used as a marker in cancer prognosis. In this study, we have determined the effect of mu-opioid receptor agonists and antagonists on the urokinase plasminogen activator secretion in MCF-7 cell line. It was shown that mu-opioid receptor agonists, such as morphine and endomorphins, greatly stimulate urokinase plasminogen activator secretion, while naloxone and MOR-selective antagonists elicit the opposite effect. The same tendency was observed also on the urokinase plasminogen activator mRNA level. However, neither agonists nor antagonists had any effect on proliferation of MCF-7 cells. The findings reported in this study may be useful in designing further experiments aimed at elucidating the role of the opioid system in cancer cells.

引用

页码：390 / 396

页数：7

共 41 条

[1] TUMOR-CELL INVASION INHIBITED BY TIMP-2
ALBINI, A
MELCHIORI, A
SANTI, L
LIOTTA, LA
BROWN, PD
STETLERSTEVENSON, WG
[J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (11) : 775 - 779
[2] Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO
[3] 2-Z
[4] Biermann JC, 2008, INT J MOL MED, V21, P251
[5] CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
[6] PREVENTION OF METASTASIS BY INHIBITION OF THE UROKINASE RECEPTOR
CROWLEY, CW
COHEN, RL
LUCAS, BK
LIU, GH
SHUMAN, MA
LEVINSON, AD
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (11) : 5021 - 5025
[7] Plasminogen activation and cancer
Dano, K
Behrendt, N
Hoyer-Hansen, G
Johnsen, M
Lund, LR
Ploug, M
Romer, J
[J]. THROMBOSIS AND HAEMOSTASIS, 2005, 93 (04) : 676 - 681
[8] The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer
Duffy, MJ
Duggan, C
[J]. CLINICAL BIOCHEMISTRY, 2004, 37 (07) : 541 - 548
[9] The urokinase plasminogen activator system: Role in malignancy
Duffy, MJ
[J]. CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (01) : 39 - 49
[10] COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia
Farooqui, M.
Li, Y.
Rogers, T.
Poonawala, T.
Griffin, R. J.
Song, C. W.
Gupta, K.
[J]. BRITISH JOURNAL OF CANCER, 2007, 97 (11) : 1523 - 1531

← 1 2 3 4 5 →